Bio-Rad Laboratories, Inc. (BIO) Stock

Bio-Rad Laboratories, Inc. (BIO) is a Technology stock trading at $376.49 (as of 2026-08-20), with a market capitalization of $10.15B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Bio-Rad Laboratories manufactures and distributes life science research and clinical diagnostic products, including reagents, instruments, and informatics systems. It operates in Life Science and Clinical Diagnostics segments, serving research institutions, pharmaceutical and biotech companies, clinical laboratories, and food producers/testing labs across multiple regions.

Understand Bio-Rad Laboratories, Inc.: how it makes money

Bio-Rad Laboratories makes and sells life science research and clinical diagnostic products, including reagents, laboratory instruments, and related items, generating revenue mainly from net sales to laboratories and clinical customers.

The Life Science profit engine is the mix of consumables versus instruments, since the company sells both (reagents and apparatus, plus laboratory instruments) and explicitly tracks a consumables versus instruments KPI.

Revenue by segment (latest quarter)
ClinicalDx$0.4B
LifeSci$0.2B

Business quality (Weak): Segment structure and key operating KPIs are clearly identified, but the provided facts do not include guidance, backlog, or additional drivers behind margins.

Valuation: At 48× earnings, BIO trades 21% below the Measuring & Control Equipment average (60×). Note: one-time items can distort reported P/E.

Bull case

  • Assay availability strength: Digital PCR - QX700 Assay Availability Coverage is reported at 99 percent.
  • Established product breadth in Life Science: Life Science includes both reagents and apparatus used in biopharmaceutical production and laboratory instruments used in research and related workflows.

Bear case

  • Potential demand and mix volatility: Operating performance can be sensitive to shifts between consumables and instruments within Life Science, since these are tracked as distinct components of the business.
  • Execution risk across technology workflows: The company operates in multiple technical areas, and reported KPIs such as Processed Chromatography - Customer Orders Pull-Forward Mix suggest results may be influenced by customer ordering timing.
Valuation — source: SEC EDGAR (first-party)
Price$376.49
Market Cap$10.15B
EV / EBITDA52.2
Price / Book1.48
Price / Sales4.09
FCF Yield5.9%
DCF Value (model)$199.34
DCF Upside vs Price-47.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.58B
Net Margin29.4%
Revenue Growth (YoY)0.7%
EPS Growth (YoY)-142.6%
FCF Growth (YoY)29.4%
Financial Health — source: SEC EDGAR
Altman Z-Score3.59 (safe)
Piotroski F-Score5/9 (moderate)
Valuation vs Sector & Industry
Sector P/E (Technology)33.9
Industry P/E (Measuring & Control Equipment)51.8
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFirst Eagle Investment Management, LLC ($725.52M)
Institutional Holders Tracked10
Congressional Trades (recent)6
Company
SectorTechnology
IndustryMeasuring & Control Equipment
CEONorman D. Schwartz
Employees7,700
CountryUS
IPO Date1980-02-27

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Waters Corporation (WAT)
  • Illumina, Inc. (ILMN)
  • Mettler-Toledo International Inc. (MTD)
  • Revvity, Inc. (RVTY)
  • Avantor, Inc. (AVTR)
  • Bruker Corporation (BRKR)
  • 10x Genomics, Inc. (TXG)
  • Alamar Biosciences, Inc. (ALMR)
BIO earnings history · BIO institutional & insider holders · BIO KPIs & operating metrics · BIO financials · BIO investor presentations & press releases · BIO SEC filings · BIO peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.